Alkermes

Expanding Mental Health Demand Will Spur Therapy Adoption Despite Risks

AnalystHighTarget

Not Invested

Consensus Narrative from 16 Analysts

Published

27 Apr 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$53.89

47.8% undervalued

15 Aug

US$28.12

-0.4%

5.9%

Author's Valuation

US$53.9

47.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates2

Shared on07 May 25
Fair value Increased 3.63%

Shared on30 Apr 25

AnalystHighTarget Fair Value

US$53.9

47.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.30%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.16%

Calculation

US$281.59m

Earnings '28

39.09x

PE Ratio '28

US$11.01b

Market Cap '28

US$11.01b

Market Cap '28

166.31m

No. shares '28

US$66.19

Share Price '28

US$66.19 Share Price '28

Discounted to 2025 @ 7.16% p.a.

US$53.79

Fair Value '25

Expanding Mental Health Demand Will Spur Therapy Adoption Despite Risks

Shared on07 May 25Fair value Increased 3.63%

Shared on30 Apr 25

Shared on07 May 25
Fair value Increased 3.63%